Zilovertamab vedotin (anti-ROR1) 是一种新型抗体-活性分子偶联物 (ADC),包含人源化单克隆抗体 zilovertamab 和抗微管细胞毒素单甲基 vedotin。Zilovertamab vedotin (anti-ROR1) 与肿瘤细胞 ROR1 结合导致快速内化、转运至溶酶体、抗体-活性分子偶联物裂解和单甲基 vedotin 释放。Zilovertamab vedotin (anti-ROR1) 诱导细胞凋亡。Zilovertamab vedotin (anti-ROR1) 可用于癌症研究。
Zilovertamab vedotin (anti-ROR1) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin (anti-ROR1) binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody–agent conjugate cleavage, and monomethyl vedotin release. Zilovertamab vedotin (anti-ROR1) induces apoptosis. Zilovertamab vedotin (anti-ROR1) can be used in research of cancer.
Purity
>90% (SDS-PAGE&SEC)
Endotoxin Level
< 1.0EU/mg